Prostate Cancer Clinical Trial
Official title:
Evaluation of an Electronic Post-Treatment Surveillance Program for Prostate Cancer Survivors (eHealth)
NCT number | NCT04486846 |
Other study ID # | Pro00104751 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2021 |
Est. completion date | March 2022 |
Verified date | June 2021 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this single institution pilot study is to determine the feasibility of implementing an eHealth prostate cancer surveillance program through the eVisit electronic medical record patient portal. The investigators will assess patient compliance and satisfaction with eVisit follow up care in lieu of in person clinic visits.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 2022 |
Est. primary completion date | March 2022 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - = 18 years old with histologically confirmed prostate cancer - Completed curative intent treatment to the prostate +/- pelvis - Deemed to be "without evidence of active disease" by treating provider with at least 1 follow up visit 3 or more months after treatment completion - MyChart account or willingness to open account - Access to the internet Exclusion Criteria: - Documented extrapelvic metastases - PSA meeting definition of recurrence (>0.2 ng/ml for prostatectomy patients or nadir + 2 ng/ml for radiation patients) and rising with doubling time less than 1 year |
Country | Name | City | State |
---|---|---|---|
United States | Duke Cancer Institute Cary | Cary | North Carolina |
United States | Duke University Medical Center | Durham | North Carolina |
United States | Durham Regional Hospital | Durham | North Carolina |
United States | Duke Raleigh Hospital | Raleigh | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients who complete all scheduled eVisits at the end of follow-up | Defined as completion of labwork and at least 80% of the questions asked at each eVisit | 12 months | |
Secondary | Feasibility of enrollment to the eVisit program | Defined as the percentage of patients who are approached for eVisit and ultimately enroll | 12 months | |
Secondary | eVisit participant reported satisfaction | Reported as the summary score from validated Brief Patient Satisfaction 10-item scale instrument assessed from "1/strongly agree" through "5/strongly disagree" | 12 months | |
Secondary | Number of participants with cancer treatment related toxicities | Defined specifically as CTCAE Grade 2 or higher GI, GU, hormonal, and sexual toxicities | 12 months | |
Secondary | Number of eVisit participants with cancer recurrence | Defined as biochemical progression (PSA >0.2 ng/ml for prostatectomy patients or nadir + 2 ng/ml for radiation patients) or metastasis (by imaging) | 12 months | |
Secondary | Financial impact of the eVisit program on participants compared to in person follow up clinic visits | Defined by the financial burden assessment completed by participants, scored from "0/not at all" through "4/very much" | 12 months | |
Secondary | Financial impact of the eVisit program on Duke University Hospital (institution) compared to in person follow up | Defined by percentage of participants/eVisits covered by insurance | 12 months | |
Secondary | Financial impact of the eVisit program on Duke University Hospital (institution) compared to in person follow up | Defined by qualitative analysis of time commitment for providers | 12 months | |
Secondary | Financial impact of the eVisit program on Duke University Hospital (institution) compared to in person follow up | Defined by qualitative analysis of reimbursement process | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |